{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:09:37Z","timestamp":1793257777339,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.tmrv.2021.06.002","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T11:02:11Z","timestamp":1624705331000},"page":"36-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Daratumumab: Beyond Multiple Myeloma"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5095-3606","authenticated-orcid":false,"given":"Kiran","family":"Ejaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9952-2252","authenticated-orcid":false,"given":"John D.","family":"Roback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean R.","family":"Stowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4909-7168","authenticated-orcid":false,"given":"Harold C.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.tmrv.2021.06.002_bib0001","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1681\/ASN.2018121254","article-title":"Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use","volume":"30","author":"Kwun","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.tmrv.2021.06.002_bib0002","unstructured":"Clinical Trials Daratumumab. 2020 [cited 7 May 2020]. Available from: https:\/\/clinicaltrials.gov\/ct2\/results?term=Daratumumab&Search=Apply&age_v=&gndr=&type=&rslt=."},{"issue":"9","key":"10.1016\/j.tmrv.2021.06.002_bib0003","first-page":"6007","article-title":"ImmunoPET imaging of CD38 expression in hepatocellular carcinoma using (64)Cu-labeled daratumumab","volume":"11","author":"Li","year":"2019","journal-title":"Am J Transl Res"},{"issue":"5","key":"10.1016\/j.tmrv.2021.06.002_bib0004","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1111\/trf.15202","article-title":"A blockage monoclonal antibody protocol as an alternative strategy to avoid anti-CD38 interference in immunohematological testing","volume":"59","author":"Chinoca Ziza","year":"2019","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.tmrv.2021.06.002_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010167","article-title":"Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma","volume":"9","author":"Saltarella","year":"2020","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.tmrv.2021.06.002_bib0006","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3390\/jcm9041195","article-title":"Resistance mechanisms towards CD38-directed antibody therapy in multiple myeloma","volume":"9","author":"Franssen","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.tmrv.2021.06.002_bib0007","first-page":"189","article-title":"Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting","author":"Viola","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.tmrv.2021.06.002_bib0008","series-title":"Initial U.S. Approval: 2015: \u00a9 2015-2020 Janssen Pharmaceutical Companies","article-title":"HIGHLIGHTS OF PRESCRIBING INFORMATION. DARZALEX\u00ae (daratumumab) injection, for intravenous use","author":"Companies","year":"2021"},{"issue":"23","key":"10.1016\/j.tmrv.2021.06.002_bib0009","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V126.23.507.507","article-title":"Daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: updated results of a phase 1\/2 study (GEN503)","volume":"126","author":"Plesner","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.tmrv.2021.06.002_bib0010","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tmrv.2021.06.002_bib0011","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.3324\/haematol.2019.219683","article-title":"Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed\/refractory multiple myeloma patients","volume":"105","author":"Kitadate","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.tmrv.2021.06.002_bib0012","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.3324\/haematol.2019.231860","article-title":"Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients","volume":"105","author":"Frerichs","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.tmrv.2021.06.002_bib0013","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood-2019-127247","article-title":"Hypogammaglobulinemia and Its implications in patients treated with daratumumab: a single institution experience","volume":"134","author":"Paul","year":"2019","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.tmrv.2021.06.002_bib0014","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1080\/10428194.2019.1636981","article-title":"Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donor","volume":"60","author":"Strunz","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.tmrv.2021.06.002_bib0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14712\/fb2020066010017","article-title":"Anti-CD38 therapy with daratumumab for relapsed\/refractory CD20-negative diffuse large b-cell lymphoma","volume":"66","author":"Vockova","year":"2020","journal-title":"Folia Biol (Praha)"},{"issue":"5","key":"10.1016\/j.tmrv.2021.06.002_bib0016","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000438731","article-title":"Treatment options for primary autoimmune hemolytic anemia: a short comprehensive review","volume":"42","author":"Salama","year":"2015","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.tmrv.2021.06.002_bib0017","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/JBM.S190327","article-title":"Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives","volume":"10","author":"Barcellini","year":"2019","journal-title":"J Blood Med"},{"issue":"19","key":"10.1016\/j.tmrv.2021.06.002_bib0018","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2018020883","article-title":"Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation","volume":"2","author":"Schuetz","year":"2018","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.tmrv.2021.06.002_bib0019","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1111\/trf.15539","article-title":"Daratumumab in combination with standard treatment for autoimmune hemolytic anemia in a pediatric patient","volume":"59","author":"Cooling","year":"2019","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.tmrv.2021.06.002_bib0020","doi-asserted-by":"crossref","first-page":"e28010","DOI":"10.1002\/pbc.28010","article-title":"Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia","volume":"67","author":"Even-Or E","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.tmrv.2021.06.002_bib0021","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.16171","article-title":"Post-allogeneic transplant evans syndrome successfully treated with daratumumab","volume":"187","author":"Blennerhassett","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2021.06.002_bib0022","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/TP.0000000000003247","article-title":"CD38 Antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection","volume":"105","author":"Doberer","year":"2020","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.tmrv.2021.06.002_bib0023","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000503951","article-title":"Daratumumab for treatment of antibody-mediated rejection after ABO-incompatible kidney transplantation","volume":"9","author":"Spica","year":"2019","journal-title":"Case Rep Nephrol Dial"},{"issue":"3","key":"10.1016\/j.tmrv.2021.06.002_bib0024","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/MOT.0000000000000537","article-title":"Current challenges and opportunities in the management of antibody-mediated rejection in lung transplantation","volume":"23","author":"Hulbert","year":"2018","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.tmrv.2021.06.002_bib0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.tracli.2020.06.008","article-title":"Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Ataca Atilla","year":"2020","journal-title":"Transfus Clin Biol"},{"issue":"21","key":"10.1016\/j.tmrv.2021.06.002_bib0026","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1182\/blood-2016-05-717140","article-title":"Pure red cell aplasia","volume":"128","author":"Means RT","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.tmrv.2021.06.002_bib0027","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood.V98.6.1687","article-title":"Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation","volume":"98","author":"Bolan","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.tmrv.2021.06.002_bib0028","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/ejh.13343","article-title":"Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab","volume":"104","author":"Salas","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.tmrv.2021.06.002_bib0029","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/s41409-019-0664-4","article-title":"Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation","volume":"55","author":"Rautenberg","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"10.1016\/j.tmrv.2021.06.002_bib0030","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMoa1807438","article-title":"Daratumumab for delayed red-cell engraftment after allogeneic transplantation","volume":"379","author":"Chapuy","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.tmrv.2021.06.002_bib0031","doi-asserted-by":"crossref","first-page":"E216","DOI":"10.1002\/ajh.25515","article-title":"Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab","volume":"94","author":"Bathini","year":"2019","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.tmrv.2021.06.002_bib0032","doi-asserted-by":"crossref","first-page":"1677-8 e3","DOI":"10.1016\/j.jaci.2016.12.955","article-title":"Could daratumumab be used to treat severe allergy?","volume":"139","author":"Blankestijn","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.tmrv.2021.06.002_bib0033","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI115092","article-title":"Glucocorticoids increase the synthesis of immunoglobulin E by interleukin 4-stimulated human lymphocytes","volume":"87","author":"Wu","year":"1991","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.tmrv.2021.06.002_bib0034","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2013-04-495341","article-title":"Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia","volume":"122","author":"Strati","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tmrv.2021.06.002_bib0035","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/cells9010077","article-title":"Is there a future for anti-cd38 antibody therapy in systemic autoimmune diseases?","volume":"9","author":"Benfaremo","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.tmrv.2021.06.002_bib0036","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13075-018-1578-z","article-title":"Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus","volume":"20","author":"Cole","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.tmrv.2021.06.002_bib0037","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00415-019-09585-6","article-title":"Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis","volume":"267","author":"Scheibe","year":"2020","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.tmrv.2021.06.002_bib0038","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/labmed\/lmz004","article-title":"Post-transfusion purpura mimicking idiopathic thrombocytopenic purpura: a case report","volume":"50","author":"Milito","year":"2019","journal-title":"Lab Med"},{"issue":"14","key":"10.1016\/j.tmrv.2021.06.002_bib0039","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/cncr.32065","article-title":"Daratumumab in multiple myeloma","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.tmrv.2021.06.002_bib0040","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/trf.15134","article-title":"The impact of Daratumumab on transfusion service costs","volume":"59","author":"Cushing","year":"2019","journal-title":"Transfusion"},{"issue":"22","key":"10.1016\/j.tmrv.2021.06.002_bib0041","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood-2016-11-749432","article-title":"Daratumumab (anti-CD38) induces loss of CD38 on red blood cells","volume":"129","author":"Sullivan","year":"2017","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.tmrv.2021.06.002_bib0042","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","article-title":"Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab","volume":"23","author":"Krejcik","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.tmrv.2021.06.002_bib0043","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/vox.12864","article-title":"Risk of RBC alloimmunization in multiple myeloma patients treated by Daratumumab","volume":"115","author":"Ye","year":"2020","journal-title":"Vox Sang"},{"issue":"3","key":"10.1016\/j.tmrv.2021.06.002_bib0044","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/bjh.16282","article-title":"Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population","volume":"188","author":"Van de Wyngaert","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.tmrv.2021.06.002_bib0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3960\/jslrt.19034","article-title":"Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy","volume":"60","author":"Kikuchi","year":"2020","journal-title":"J Clin Exp Hematop"},{"issue":"5","key":"10.1016\/j.tmrv.2021.06.002_bib0046","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/bjh.13339","article-title":"Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience","volume":"169","author":"Vidler","year":"2015","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.tmrv.2021.06.002_bib0047","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/ajh.24460","article-title":"Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes","volume":"91","author":"Habibi","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.tmrv.2021.06.002_bib0048","doi-asserted-by":"crossref","first-page":"231","DOI":"10.7326\/0003-4819-93-2-231","article-title":"Delayed hemolytic transfusion reaction presenting as sickle-cell crisis","volume":"93","author":"Diamond","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tmrv.2021.06.002_bib0049","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2019.224709","article-title":"Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal","author":"Thein","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.tmrv.2021.06.002_bib0050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/trf.13379","article-title":"Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series","volume":"56","author":"Nickel","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2021.06.002_bib0051","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/trf.15010","article-title":"Multiple hemolytic transfusion reactions misinterpreted as severe vaso-occlusive crisis in a patient with sickle cell disease","volume":"59","author":"Dean","year":"2018","journal-title":"Transfusion"},{"issue":"12","key":"10.1016\/j.tmrv.2021.06.002_bib0052","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/ajh.24908","article-title":"Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease","volume":"92","author":"Narbey","year":"2017","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.tmrv.2021.06.002_bib0053","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2141.2008.07189.x","article-title":"Platelet transfusion refractoriness","volume":"142","author":"Hod","year":"2008","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.tmrv.2021.06.002_bib0054","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.tmrv.2019.09.006","article-title":"Examining the role of complement in predicting, preventing, and treating hemolytic transfusion reactions","volume":"33","author":"Arthur","year":"2019","journal-title":"Transfus Med Rev"},{"issue":"8","key":"10.1016\/j.tmrv.2021.06.002_bib0055","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2015-09-669770","article-title":"Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients","volume":"127","author":"Dumas","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2021.06.002_bib0056","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.3324\/haematol.2018.194670","article-title":"Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease","volume":"103","author":"Chonat","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.tmrv.2021.06.002_bib0057","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.3324\/haematol.2020.262006","article-title":"Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease","volume":"105","author":"Chonat","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.tmrv.2021.06.002_bib0058","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3324\/haematol.2020.253856","article-title":"Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease","volume":"105","author":"Floch","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.tmrv.2021.06.002_bib0059","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/MOH.0000000000000610","article-title":"Role of complement in alloimmunization and hyperhemolysis","volume":"27","author":"Chonat","year":"2020","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.tmrv.2021.06.002_bib0060","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3389\/fimmu.2018.00676","article-title":"Complement component 3 negatively regulates antibody response by modulation of red blood cell antigen","volume":"9","author":"Mener","year":"2018","journal-title":"Front Immunol"},{"issue":"22","key":"10.1016\/j.tmrv.2021.06.002_bib0061","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121631","article-title":"Complement serves as a switch between CD4+ T cell-independent and -dependent RBC antibody responses","volume":"3","author":"Mener","year":"2018","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.tmrv.2021.06.002_bib0062","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2017010124","article-title":"Recipient priming to one RBC alloantigen directly enhances subsequent alloimmunization in mice","volume":"2","author":"Patel","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.tmrv.2021.06.002_bib0063","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020009376","article-title":"Marginal Zone B Cells Mediate a CD4 T cell dependent extrafollicular antibody response following RBC transfusion in mice","author":"Zerra","year":"2021","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.tmrv.2021.06.002_bib0064","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1182\/blood-2017-05-782912","article-title":"Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A","volume":"130","author":"Zerra","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2021.06.002_bib0065","article-title":"Non-human glycans can regulate anti-fviii antibody formation in mice","author":"Arthur","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.tmrv.2021.06.002_bib0066","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1111\/j.1537-2995.2009.02199.x","article-title":"Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death","volume":"49","author":"Chadebech","year":"2009","journal-title":"Transfusion"},{"issue":"14","key":"10.1016\/j.tmrv.2021.06.002_bib0067","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2015-10-673426","article-title":"CD8+ T cells mediate antibody-independent platelet clearance in mice","volume":"127","author":"Arthur","year":"2016","journal-title":"Blood"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796321000237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796321000237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:20:27Z","timestamp":1760138427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796321000237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0887796321000237"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2021.06.002","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daratumumab: Beyond Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2021.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}